QLC5508: Clinical Trials

4 trials of QLC5508, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 not yet recruiting, 2 recruiting. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Not yet recruiting 2, Recruiting 2

Follow QLC5508: new trials by email Literature Review of QLC5508 trials Research Report on QLC5508

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
QLC5508, QL2107, Tislelizumab - Extensive-stage Small Cell Lung Cancer
Phase 3RecruitingQilu Pharmaceutical Co., Ltd.5562026-10-272026-10-30
QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
Investigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen), QLC5508 - Extrapulmonary Neuroendocrine Carcinoma
Phase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.2702026-10-262026-10-26
QLC5508 in Participants With Metastatic Prostate Cancer
QLC5508, Docetaxel - Prostate Cancer
Phase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.7002026-06-202026-06-08
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
QLC5508, Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride) - Esophageal Squamous Cell Carcinoma (ESCC)
Phase 3RecruitingQilu Pharmaceutical Co., Ltd.4662026-04-202026-04-24

Conditions studied

Esophageal Squamous Cell Carcinoma (1)  ·  Prostatic Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

Qilu Pharmaceutical Co., Ltd. (4)

Countries

China (2)